Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.


Last Trade
0.54 (1.27%)
B/A Size

Market Hours

Closing Price
Day's Change
2.32 (5.78%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

New Study Again Shows 22nd Century's Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation

9:43 am ET November 7, 2022 (Globe Newswire) Print
New Study Again Shows 22nd Century's Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking CessationGlobeNewswireNovember 07, 2022
  • Reduced nicotine cigarettes increase cessation, decrease consumption, decrease dependence, and reduce toxicants
  • Study dispels common misconception that reduced nicotine cigarettes worsen general health and mental health problems

BUFFALO, N.Y., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, highlighted a recent study that found switching to 22nd Century's reduced nicotine content (RNC) cigarettes "reduces toxicant exposure and increases smoking cessation without worsening mental health among smokers with mood or anxiety disorders."

The study conclusively dispelled a common misconception that RNC's may exacerbate general health and mental health problems. The study also concluded that a national nicotine reduction policy for cigarettes will likely result in reduced nicotine absorption and likely result in greater smoking cessation from smokers with mood and anxiety disorders.

The study examined adult smokers with a current or lifetime anxiety or unipolar mood disorder. The participants were randomly assigned to smoke conventional cigarettes or 22nd Century's RNC research cigarettes. Adult smokers who were assigned to smoke 22nd Century's RNC cigarettes had significantly lower cigarette consumption, lower cigarette dependence, lower plasma cotinine (metabolite of nicotine), and lower exhaled carbon-monoxide than smokers assigned to the conventional group.

At the end of the study, despite having selected only participants not intending to stop smoking, those randomized to the group using 22nd Century's RNC cigarettes were more likely to have quit smoking.

"Study after study, reduced nicotine cigarettes are shown to be beneficial to adult smokers. The combination of reduced nicotine cigarettes and a proposed nicotine standard have the potential to forever change the trajectory of public health by helping adult smokers smoke less," said James A. Mish, chief executive officer of 22nd Century Group. "Based on last week's comments from FDA's Center for Tobacco Products Director, Dr. Brian King, we are confident the FDA will use its existing authority to advance both a reduced nicotine policy and a menthol ban. These policies and 22nd Century's reduced nicotine cigarettes are expected to save millions of lives and increase the chances that current smokers quit. Our VLN(R) reduced nicotine content cigarettes are backed by clear science and evidence which support FDA's proposed product standards and are the only FDA-authorized combustible product able to meet the stringent reduced nicotine levels determined by the FDA to be 'minimally or non-addictive'."

In related news, a webinar hosted by Mitchell Hamline School of Law's Public Health Law Center on November 3, 2022, featured FDA's Center for Tobacco Product (CTP) Director Dr. Brian King publicly stating that the proposed menthol standard remains a key priority for him, the FDA, and CTP. The FDA is currently in the process of reviewing the comments they received as they move forward with the proposed rule. Dr. King also noted that the FDA remains committed to using its regulatory authority to protect public health and intends to finalize a nicotine standard for the maximum level of nicotine allowed in combusted tobacco products. The reduced nicotine rule is of high priority for the FDA as it has profound health benefits in terms of preventing initiation of smoking and promoting cessation for current smokers and a huge potential to have a positive impact on public health.

22nd Century believes that the menthol cigarette ban could leave VLN(R) Menthol King as the only combustible menthol cigarette on the market, providing a critical off-ramp to help current menthol smokers to smoke less. The Company expects VLN(R) Menthol King reduced nicotine cigarettes to be exempted from FDA's menthol ban under procedures detailed in FDA's proposed rule announced April 28, 2022. 22nd Century's VLN(R) cigarette products are the only FDA-authorized combustible cigarette able to meet the stringent reduced nicotine content product standard under the FDA's Comprehensive Plan requiring that all cigarettes be made "minimally or non-addictive."

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN(R) at

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 1, 2022, and in the Company's Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200

Primary Logo

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.